Signaling via hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors

Current Opinion in Cell Biology

Volumn 8, Issue 2, 1996, Pages 139-145

  Ten Dijke, Peter ^a   Miyazono, Kohei ^b   Heldin, Carl Henrik ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

^b CANCER INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN SERINE THREONINE KINASE; RECEPTOR SUBTYPE; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

DROSOPHILA; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION;

EID: 0029944441     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-0674(96)80058-5     Document Type: Article

References (58)

1. •].
2. •].
3. Winnier G, Blessing M, Labosky PA, Hogan BL: Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev 1995, 9:2105-2116.
4. Storm EE, Huynh TV, Copeland NG, Jenkins NA, Kingsley DM, Lee S-J: Limb alterations in brachypodism mice due to mutations in a new member of the TGFβ-superfamily. Nature 1994, 368:639-642.
5. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D et al.: Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 1992, 359:693-699.
6. 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993, 90:770-774.
7. Letterio JJ, Geiser AG, Kulkarni AB, Roche NS, Sporn MB, Roberts AB: Maternal rescue of transforming growth factor-β1 null mice. Science 1994, 264:1936-1938.
8. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ: Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice. Development 1995, 121:1845-1854.
9. Daopin S, Li M, Davies DR: Crystal structure of TGF-β2 refined at 1.8 Ȧ resolution. Proteins 1993, 17:176-192.
10. Schlunegger MP, Grütter MG: Refined crystal structure of human transforming growth factor β2 at 1.95 Ȧ resolution. J Mol Biol 1993, 231:445-458.
11. Ebner R, Chen R-H, Lawler S, Zioncheck TF, Derynck R: Determination of type I receptor specificity by type II receptors for TGF-β and activin. Science 1993, 262:900-902.
12. Attisano L, Cárcamo J, Ventura F, Weis F, Massagué J, Wrana JL: Identification of human activin and TGFβ type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993, 75:671-680.
13. Franzén P, Ten Dijke P, Ichijo H, Yamashita H, Schulz P, Heldin C-H, Miyazono K: Cloning of a TGFβ type I receptor that forms a heteromeric complex with the TGFβ type II receptor. Cell 1993, 75:681-692.
14. Tsuchida K, Mathews LS, Vale WW: Cloning and characterization of a transmembrane serine kinase that acts as an activin type I receptor. Proc Natl Acad Sci USA 1993, 90:11242-11246.
15. Bassing CH, Yingling JM, Howe DJ, Wang T, He WW, Gustafson ML, Shah P, Donahoe PK, Wang X-F: A transforming growth factor β type I receptor that signals to activate gene expression. Science 1994, 263:87-89.
16. Ten Dijke P, Yamashita H, Ichijo H, Franzén P, Laiho M, Miyazono K, Heldin C-H: Characterization of type I receptors for transforming growth factor-β and activin. Science 1994, 264:101-104.
17. Cárcamo J, Weis FMB, Ventura F, Wieser R, Wrana JL, Attisano L, Massagué; J: Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor β and activin. Mol Cell Biol 1994, 14:3810-3821.
18. Ten Dijke P, Yamashita H, Sampath TK, Reddi AH, Estevez M, Riddle DL, Ichijo H, Heldin C-H, Miyazono K: Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem 1994, 269:16985-16988.
19. •].
20. •].
21. •].
22. •].
23. •].
24. Mathews LS, Vale WW: Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell 1991, 65:973-982.
25. Attisano L, Wrana JL, Cheifetz S, Massagué J: Novel activin receptors: distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors. Cell 1992, 68:97-108.
26. Lin HY, Wang X-F, Ng-Eaton E, Weinberg RA, Lodish HF: Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell 1992, 68:775-785.
27. Estevez M, Attisano L, Wrana JL, Albert PS, Massagué J, Riddle, DL: The daf-4 gene encodes a bone morphogenetic protein receptor controlling C. elegans dauer larvae development Nature 1993, 365:644-649.
28. •].
29. •].
30. •].
31. Letsou A, Arora K, Wrana JL, Simin K, Twombly V, Jamal J, Staehling-Hampton K, Hoffman FM, Gelbart WM, Massagué J, O'Conner MB: Drosophila dpp signaling is mediated by the punt gene product: a dual ligand-binding type II receptor of the TGFβ receptor family. Cell 1995, 80: 899-908. Punt is shown to act as a type II receptor for dpp. In the presence, but not in the absence, of saxophone and thick veins, punt is shown to bind BMP-2.
32. Ruberte E, Marty T, Affolter M, Basler K: An absolute requirement for both the type II and type I receptors, punt and thick veins, for dpp signaling in vivo. Cell 1995, 80:890-898. Identification of punt as a type II receptor for dpp in vivo. Mutations that abolish punt activity result in a phenotype indistinguishable from those produced by mutations that result in loss of dpp or thick veins activity. Both punt and thick veins are essential for dpp signaling and their function cannot be substituted by that of other receptors in vivo.
33. Wrana JL, Attisano L, Cárcamo J, Zentella A, Doody J, Laiho M, Wang X-F, Massagué J: TGFβ signals through a heteromeric protein kinase receptor complex. Cell 1992, 71:1003-1014.
34. Xu J, Matsuzaki K, McKeehan K, Wang F, Kan M, McKeehan WL: Genomic structure and cloned cDNAs predict that four variants in the kinase domain of serine/threonine kinase receptors arise by alternative splicing and poly(A) addition. Proc Natl Acad Sci USA 1994, 91:7957-7961.
35. Yamashita H, ten Dijke P, Huylebroeck D, Sampath TK, Andries M, Smith JC, Heldin C-H, Miyazono K: Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J Cell Biol 1995, 130:217-226. ActR-IIs are shown to act as functional receptors for osteogenic protein-1 in addition to activins. Some of the biological effects of activin are shown to be shared with osteogenic protein-1, including growth inhibition, erythroid differentiation, and inactivation of their biological activity by follistatin.
36. Matzuk MM, Kumar TR, Bradley A: Different phenotypes for mice deficient in either activins or activin type II receptor. Nature 1995, 374:356-360. Mice deficient in ActR-II show reproductive defects that are consistent with a role of activin in stimulation of follicle-stimulating-hormone synthesis in the pituitary gonadotrophs. However, defects in mandible development that are observed in ActR-II-deficient mice are not observed in activin-deficient mice, suggesting that ligands other than activin may act through ActR-II.
37. Yamashita H, ten Dijke P, Franzén P, Miyazono K, Heldin C-H: Formation of hetero-oligomeric complexes of type I and type II receptors for transforming growth factor-β. J Biol Chem 1994, 269:20172-20178.
38. Henis YI, Moustakas A, Lin HY, Lodish HF: The types II and III transforming growth factor-β receptors form homo-oligomers. J Cell Biol 1994, 126:139-154.
39. Chen R-H, Derynck R: Homomeric interactions between type II transforming growth factor-β receptors. J Biol Chem 1994, 269:22868-22874.
40. Okadome T, Yamashita H, Franzén P, Morén A, Heldin C-H, Miyazono K: Distinct roles of the intracellular domains of transforming growth factor-β type I and type II receptors in signal transduction. J Biol Chem 1994, 269:30753-30756.
41. Vivien D, Attisano L, Wrana JL, Massagué J: Signaling activity of homologous and heterologous transforming growth factor-β receptor kinase complexes. J Biol Chem 1995, 270:7134-7141.
42. Ventura F, Doody J, Liu F, Wrana JL, Massagué J: Reconstitution and transphosphorylation of TGF-β receptor complexes. EMBO J 1994, 13:5581-5589.
43. Chen F, Weinberg RA: Biochemical evidence for the autophosphorylation and transphosphorylation of transforming growth factor β receptor kinases. Proc Natl Acad Sci USA 1995, 92:1565-1569.
44. Chen RH, Moses HL, Maruoka EM, Derynck R, Kawabata M: Phosphorylation-dependent interaction of the cytoplasmic domains of the type I and type II transforming growth factor-β receptors. J Biol Chem 1995, 270:12235-12241.
45. Chen R-H, Ebner R, Derynck R: Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-β activities. Science 1993, 260:1335-1338.
46. Wieser R, Attisano L, Wrana JL, Massagué J: Signaling activity of transforming growth factor β type II receptors lacking specific domains in the cytoplasmic region. Mol Cell Biol 1993, 13:7239-7247.
47. Hemmati-Brivanlou A, Melton DA: Inhibition of activin receptor signaling promotes neuralization in Xenopus. Cell 1994, 77:273-281. Expression of truncated ActR-II is shown to convert prospective ectoderm into neural tissue. Neuralization may occur when the inhibitory signal of an activin-like protein is prevented.
48. Schulte-Merker S, Smith JC, Dale L: Effects of truncated activin and FGF receptors and of follistatin on the inducing activities of BVg1 and activin: does activin play a role in mesoderm induction? EMBO J 1994, 13:3533-3541. Mesoderm induction by Vg1, a member of the BMP subgroup, was blocked by truncated ActR-II, suggesting that not only activins but also BMP-like ligands may act through this receptor. Furthermore, follistatin, an inhibitor of activin, shows no inhibitory effect on mesoderm formation, suggesting that activin does not act as an endogenous mesoderm-inducing factor in Xenopus.
49. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J: Mechanism of activation of TGF-β receptor. Nature 1994, 370:341-347. An elegant paper describing a model for the molecular mechanism of TGFβ receptor activation. The type II receptor is a constitutively active kinase even in the absence of ligand. Ligand bound to the type II receptor is recognized by the type I receptor, which, upon association with the type II receptor, becomes phosphorylated, predominantly in its GS domain. The phosphorylated and activated type I receptor propagates signals to intracellular downstream elements of the TGF-β receptor complex.
50. Wieser R, Wrana JL, Massagué J: GS domain mutations that constitutively activate TβR-I, the downstream signaling component in the TGF-β receptor complex. EMBO J 1995, 14:2199-2208. A mutational analysis of serine and threonine residues in the juxtamembrane region of the type I receptor reveals that replacement of threonine 204 with an aspartic acid residue generates a type I receptor that signals in the absence of ligand and type II receptor. This finding implies that the type I receptor acts downstream of the type II receptor, and that its activation is essential and sufficient for most TGF-β mediated responses.
51. Cárcamo J, Zentella A, Massagué J: Disruption of transforming growth factor β signaling by a mutation that prevents transphosphorylation within the receptor complex. Mol Cell Biol 1995, 15:1573-1581.
52. Wang T, Donahoe PK, Zervos AS: Specific interaction of type I receptors of the TGF-β family with the immunophilin FKBP-12. Science 1994, 265:674-676.
53. Kawabata M, Imamura T, Miyazono K, Engel ME, Moses HL: Interaction of the TGF-β type I receptor with farnesyl transferase-α. J Biol Chem 1995, 270:29628-29631.
54. Chen R-H, Mieltinen PJ, Maruoka EM, Choy L, Derynck R: A WD-domain protein that is associated with and phosphorylated by the type II TGF-β receptor. Nature 1995, 377:548-552.
55. Arora K, Dai H, Kazuko SG, Jamal J, O'Conner MB, Letsou A, Warrior R: The Drosophila schnurri gene acts in the dpp/TGFβ signaling pathway and encodes a transcription factor homologous to the human MBP family. Cell 1995, 81:781-790.
56. Grieder NC, Nellen D, Burke R, Basler K, Affolter M: schnurri is required for Drosophila dpp signaling and encodes a zinc finger protein similar to the mammalian transcription factor PRDII-BF1. Cell 1995, 81:791-800.
57. Ming M, Ewen ME, Pereira MEA: Trypanosome invasion of mammalian cells requires activation of the TGFβ signaling pathway. Cell 1995, 82:287-296. Activation of the TGF-β signaling pathway is shown to be required for entry of Trypanosoma cruzi into host cells. Trypanosoma itself may activate this pathway.
58. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B et al.: Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338. Colon cancer cell lines with high rates of microsatellite instability caused by defective mismatch repair are shown to have inactivating mutations in the gene encoding the TGF-β type II receptor. This study suggests that type II receptor inactivation, which leads to escape from TGF-β mediated growth inhibition, may contribute to tumor progression.